FlowTriever vs EKOS Indications — Comprehensive Guide

Understanding the Importance of FlowTriever vs EKOS Indications

For healthcare providers, selecting the right medical device for treating pulmonary embolism (PE) can be a complex decision. FlowTriever and EKOS are two prominent tools in this field, each designed for specific clinical scenarios and patient profiles. FlowTriever is a mechanical thrombectomy device, FDA-cleared for the treatment of PE without the need for thrombolytics, reducing the risk of bleeding complications. This device is particularly indicated for patients who have contraindications to thrombolytics or when rapid clot removal is necessary.

On the other hand, EKOS (EkoSonic Endovascular System) utilizes ultrasound-assisted catheter-directed thrombolysis, enhancing the penetration of thrombolytic drugs into the clot. This method is indicated for patients where thrombolytics are deemed appropriate, and it is particularly effective in patients with larger clot burdens. Clinical trials have shown that EKOS can reduce the right ventricular to left ventricular diameter ratio, a key marker of PE severity.

From a practice economics perspective, the choice between FlowTriever and EKOS may also be influenced by cost considerations, with FlowTriever potentially offering a cost-effective solution due to reduced hospital stay durations. Both devices are integral to modern interventional radiology practices, and understanding their indications can lead to optimized patient outcomes. As healthcare systems increasingly focus on value-based care, the decision between these technologies should be informed by both clinical efficacy and economic impact.

At a Glance

The FlowTriever system is particularly advantageous in scenarios where rapid mechanical thrombectomy is required without the need for thrombolytic drugs, making it a preferred choice in cases with increased bleeding risk.

EKOS, on the other hand, leverages ultrasound to enhance thrombolytic drug delivery, allowing for lower doses and potentially reducing systemic bleeding complications. This approach is favored in Europe.

Both devices are FDA-cleared, ensuring their safety and efficacy in clinical settings. FlowTriever’s compatibility with standard catheter systems reduces the need for additional capital investment, while EKOS requires specific ultrasound equipment, which may contribute to higher initial costs. However, its ability to use lower thrombolytic doses can lead to cost savings over time in drug expenses.

Support and training are critical for both systems. FlowTriever offers comprehensive training, facilitating quicker adoption and reducing procedure-related complications. EKOS provides dedicated technical support, ensuring optimal device performance and user proficiency.

FlowTriever Deep Dive

FlowTriever, developed by Inari Medical, is recognized for its ability to perform mechanical thrombectomy without the need for thrombolytic drugs. It was designed specifically to address the needs of patients with PE, a life-threatening condition characterized by blood clots in the lungs. FlowTriever’s standout feature is its ability to rapidly remove large clots, which can be critical in acute situations. The device is cleared by the FDA and is primarily used by interventional radiologists in both hospital and outpatient settings.

The ideal customer for FlowTriever is a healthcare provider focused on minimizing the use of thrombolytics, which can reduce the risk of bleeding complications. Some limitations include the need for specialized training to operate the device effectively. However, Inari Medical offers comprehensive training and support to ensure optimal usage.

In addition to these features, the GigHz PE Triage Calculator can be a valuable tool for assessing patient risk and determining the most appropriate treatment pathway.

EKOS Deep Dive

EKOS, a product of Boston Scientific, employs ultrasound-assisted thrombolysis to enhance the dissolution of clots. By using ultrasound waves, EKOS allows for lower doses of thrombolytic drugs, which can reduce the risk of bleeding. The device is well-suited for cardiologists and interventional radiologists who manage patients with PE in hospital settings.

EKOS is particularly beneficial for patients who may be at higher risk from standard thrombolytic dosages. The technology is FDA-cleared and requires specific ultrasound equipment, which can be seen as a limitation in terms of setup and compatibility with other systems. However, Boston Scientific provides dedicated technical support to assist healthcare providers in integrating EKOS into their treatment protocols.

For broader insights into the application of these devices, the GigHz PE Triage Calculator offers valuable data to guide clinical decision-making.

Head-to-Head — Where Each Wins

• Effectiveness in Rapid Clot Removal: FlowTriever wins due to its mechanical thrombectomy capabilities, allowing for immediate clot extraction without thrombolytics.
• Reduced Risk of Bleeding: EKOS wins as it uses ultrasound to enable lower doses of thrombolytics, minimizing bleeding risks.
• Ease of Use: FlowTriever wins with its compatibility with standard catheter systems, requiring less specialized equipment.
• Support and Training: Both offer robust support, but FlowTriever’s comprehensive training programs provide an edge for new users.
• Integration with Hospital Systems: EKOS wins if existing ultrasound equipment is already compatible, providing seamless integration.

When Neither is the Right Answer — and What Else to Consider

For healthcare providers who find that neither FlowTriever nor EKOS perfectly fit their needs, the GigHz PE Triage Calculator can offer alternative pathways by evaluating patient-specific data to recommend the most suitable treatment options.This tool is designed to help pinpoint the most effective intervention based on current clinical guidelines and patient outcomes.

Additionally, exploring options like the physician AI tools directory at physicianaitools.com can provide further insight into a wide range of decision-support tools available in the market.

Moreover, providers might consider enrolling in specialized training programs such as the Advanced Pulmonary Embolism Response Team (PERT) Consortium workshops. These programs are particularly beneficial in complex cases where traditional methods like FlowTriever and EKOS might not be suitable. Finally, staying updated with peer-reviewed journals and clinical trials can provide insights into emerging therapies.

Frequently asked questions

How do FlowTriever and EKOS differ in treating PE?

FlowTriever uses mechanical thrombectomy to remove clots without thrombolytics, while EKOS employs ultrasound to enhance thrombolysis with lower drug doses.

Is FlowTriever suitable for all PE patients?

FlowTriever is ideal for patients who need rapid clot removal without thrombolytics, but may not be suitable for all, depending on the patient’s risk profile.

What are the main advantages of using EKOS?

EKOS allows for lower doses of thrombolytics, reducing bleeding risks, and is compatible with specific ultrasound equipment for enhanced clot dissolution.

Can these devices be used in outpatient settings?

FlowTriever is versatile and can be used in both hospital and outpatient settings, while EKOS is primarily used in hospital environments.

How can I decide which device to use for my patients?

Consider patient-specific factors and use tools like the GigHz PE Triage Calculator to assess the most appropriate treatment approach.

Last reviewed by Pouyan Golshani, MD — 2026-06-23.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — June 27, 2026